Takegami Yasuhiko, Osawa Yusuke, Funahashi Hiroto, Asamoto Takamune, Ido Hiroaki, Otaka Keiji, Tanaka Shinya, Asai Hiroshi, Yokoi Hiroyuki, Imagama Shiro
Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
Drugs Aging. 2025 May;42(5):435-444. doi: 10.1007/s40266-025-01194-5. Epub 2025 Apr 29.
Polypharmacy is common in older patients and associated with adverse outcomes. However, the association with outcomes in patients with intertrochanteric fractures remains unclear. This study aimed to investigate associations between polypharmacy and 1-year survival (primary outcome) and postoperative complications (secondary outcome), in older patients undergoing surgical treatment for intertrochanteric fractures.
This multicenter retrospective study initially identified 1864 patients who underwent surgical treatment for intertrochanteric fractures between 2016 and 2020. We excluded those aged < 65 years, with polytrauma, or with Charlson Comorbidity Index (CCI) > 3 or insufficient data. Patients were classified into polypharmacy (≥ 5 medications) and non-polypharmacy (< 5 medications) groups. We performed two analyses: (1) complete case analysis using 1:1 propensity score matching (498 pairs) with variables including age, sex, body mass index (BMI), CCI, residence before admission, fracture type, American Society of Anesthesiologists (ASA) physical status (PS), and Parker Mobility Score, followed by Kaplan-Meier survival analysis with log-rank test and chi-squared test for complications and (2) multivariate Cox regression analysis using multiple imputation (CART method, five imputed datasets) of the eligible cohort (N = 1608), adjusting for the same variables.
In the matched cohort, the 1-year survival rate was significantly lower in the polypharmacy group (91.3%; 95% CI 87.7-93.8) compared with the non-polypharmacy group (94.0%; 95% CI 90.9-96.1; P = 0.027). Postoperative complications showed no significant differences between groups. Cox regression analysis revealed that advanced age, male sex, ASA-PS, and polypharmacy were associated with decreased survival, while higher Parker Mobility Score and normal and higher BMI showed improved survival.
Polypharmacy was associated with lower postoperative survival in older patients with intertrochanteric fractures and few comorbidities. As a potentially modifiable factor, medication review through multidisciplinary collaboration might contribute to improved outcomes.
多重用药在老年患者中很常见,且与不良后果相关。然而,其与粗隆间骨折患者预后的关联仍不明确。本研究旨在调查接受粗隆间骨折手术治疗的老年患者中,多重用药与1年生存率(主要结局)和术后并发症(次要结局)之间的关联。
这项多中心回顾性研究最初纳入了2016年至2020年间接受粗隆间骨折手术治疗的1864例患者。我们排除了年龄<65岁、有多发伤、Charlson合并症指数(CCI)>3或数据不足的患者。患者被分为多重用药组(≥5种药物)和非多重用药组(<5种药物)。我们进行了两项分析:(1)使用1:1倾向评分匹配(498对)进行完全病例分析,变量包括年龄、性别、体重指数(BMI)、CCI、入院前居住地、骨折类型、美国麻醉医师协会(ASA)身体状况(PS)和帕克活动评分,随后进行Kaplan-Meier生存分析,并对并发症进行对数秩检验和卡方检验;(2)对符合条件的队列(N = 1608)使用多重填补(CART方法,五个填补数据集)进行多变量Cox回归分析,对相同变量进行调整。
在匹配队列中,多重用药组的1年生存率(91.3%;95%CI 87.7-93.8)显著低于非多重用药组(94.0%;95%CI 90.9-96.1;P = 0.027)。两组术后并发症无显著差异。Cox回归分析显示,高龄、男性、ASA-PS和多重用药与生存率降低有关,而较高的帕克活动评分以及正常和较高的BMI与生存率提高有关。
多重用药与合并症较少的老年粗隆间骨折患者术后生存率较低有关。作为一个潜在的可改变因素,通过多学科协作进行药物审查可能有助于改善预后。